Intech Investment Management LLC Invests $52,000 in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Intech Investment Management LLC bought a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the third quarter, Holdings Channel reports. The fund bought 37,495 shares of the company’s stock, valued at approximately $52,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in shares of Lyell Immunopharma by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock worth $68,000 after acquiring an additional 19,287 shares in the last quarter. SG Americas Securities LLC boosted its stake in Lyell Immunopharma by 78.1% in the 3rd quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock worth $79,000 after purchasing an additional 25,247 shares during the period. Dimensional Fund Advisors LP grew its position in Lyell Immunopharma by 197.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock worth $58,000 after purchasing an additional 26,635 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Lyell Immunopharma by 37.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company’s stock valued at $186,000 after purchasing an additional 36,715 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Lyell Immunopharma by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock valued at $974,000 after purchasing an additional 38,487 shares in the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Stock Down 1.7 %

LYEL opened at $0.90 on Monday. Lyell Immunopharma, Inc. has a 12-month low of $0.85 and a 12-month high of $3.26. The firm has a market capitalization of $264.17 million, a P/E ratio of -1.14 and a beta of -0.45. The stock’s 50 day moving average price is $1.09 and its two-hundred day moving average price is $1.50.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.03 million for the quarter. As a group, analysts anticipate that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on LYEL shares. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 12th. Bank of America downgraded shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $6.00 to $1.00 in a research report on Wednesday, October 30th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.